首页> 外文期刊>The Journal of Urology >Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy?
【24h】

Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy?

机译:回肠新膀胱的选择是否会刺激患者和医生做出早期膀胱切除术的决定?

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: The primary goal of bladder replacement is to attempt to improve patient quality of life, not to increase survival, affect cancer prognosis or decrease renal metabolic complications. Nevertheless, we retrospectively determined whether orthotopic bladder replacement has an impact on the decision to perform cystectomy. MATERIALS AND METHODS: From April 1986 to September 1994, 213 men a mean of 63 years old with stages pT2N0M0 to pT4N0M0 invasive bladder cancer were referred to our department for cystectomy. For 135 patients who underwent an ileal neobladder procedure and 78 who underwent conduit diversion median followup was 4.8 and 3.5 years, respectively. We evaluated the interval from the primary diagnosis of bladder cancer to cystectomy as well as the number of previous transurethral bladder resections. The 5-year cancer specific survival rates were calculated using the Kaplan-Meier method. The Wilcoxon and log rank tests, and the Cox proportional hazards model were used to determine statistical significance. RESULTS: In the neobladder and conduit groups an average of 2.1 (range 1 to 18) and 4.1 (range 1 to 15) transurethral bladder resections was performed, respectively. Interval from the primary diagnosis to cystectomy was 11.8 months in the neobladder and 16.7 months in the conduit group. Cystectomy was performed 4.1 months after the diagnosis of invasive cancer in the neobladder group, whereas radical surgery was delayed for 15.4 months in the conduit group. Cancer specific 5-year survival rates were 76.6 and 28.35% in the neobladder and conduit groups, respectively. After stratifying according to tumor stage the 5-year survival rate was significantly higher for all disease stages in the neobladder than in the conduit group. The proportional hazards model revealed that this difference was not due to patient age at disease stages pT3bN0 and pT4N0 or by American Society of Anesthesiologists score. Independent prognostic factors for survival were diversion type and age. Delayed cystectomy was a risk factor only in advanced disease stages. CONCLUSIONS: These data suggest that the ileal neobladder may decrease physician reluctance to perform cystectomy early in the disease process, increasing the survival rate. They also demonstrate that the ileal neobladder option significantly affects an earlier patient and physician decision in favor of cystectomy.
机译:目的:膀胱置换术的主要目标是试图改善患者的生活质量,而不是增加生存率,影响癌症的预后或减少肾脏代谢并发症。尽管如此,我们回顾性地确定了原位膀胱置换术是否对进行膀胱切除术的决定有影响。材料与方法:从1986年4月至1994年9月,将213名平均年龄63岁,患有pT2N0M0至pT4N0M0浸润性膀胱癌的男性转诊至我们的膀胱切除术科。对于135例行回肠新膀胱手术的患者和78例行导管分流术的患者,中位随访时间分别为4.8年和3.5年。我们评估了从初步诊断膀胱癌到膀胱切除术的间隔以及以前经尿道膀胱切除术的次数。使用Kaplan-Meier方法计算5年癌症特异性生存率。使用Wilcoxon和log rank检验,以及Cox比例风险模型确定统计显着性。结果:在新膀胱和导管组中,平均分别进行了2.1次(范围1至18)和4.1(范围1至15)的经尿道膀胱切除术。从初次诊断到膀胱切除的间隔在新膀胱中为11.8个月,在导管组中为16.7个月。诊断为新膀胱组浸润性癌后4.1个月进行膀胱切除术,而导管组则进行根治性手术延迟了15.4个月。在新膀胱和导管组中,特定于癌症的5年生存率分别为76.6和28.35%。根据肿瘤分期,新膀胱的所有疾病分期的5年生存率均显着高于导管组。比例风险模型显示,这种差异不是由于患者在疾病阶段pT3bN0和pT4N0的年龄或美国麻醉医师学会评分造成的。生存的独立预后因素是转移类型和年龄。延迟膀胱切除术仅在疾病晚期才是危险因素。结论:这些数据表明回肠新膀胱可能会减少医师在疾病过程早期不愿进行膀胱切除术的意愿,从而提高存活率。他们还证明回肠新膀胱的选择会显着影响早期患者和医师决定进行膀胱切除术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号